Hemerion addresses upfront management of newly diagnosed glioblastoma, during surgery, before any adjuvant treatment or drug can be delivered, making Hemerion technology a breakthrough innovation that significantly improves both survival and quality of life in patients.
Hemerion solutions complement and enhance glioblastoma current treatment
Glioblastoma is the most common and most devastating malignant brain tumor. There is no known cure for this disease: the tumor progression is only slowed and reduced through surgery, radiotherapy and chemotherapy.
Hemerion technology dramatically improves the existing treatment outcomes, patients’ survival and quality of life.
Hemerion solutions bring together novel pharmaceutical and photonic therapies
Hemerion technology associates a drug (Pentalafen®) with innovative photonic treatments (Heliance Solution). Molecule used for our treatment selectively bond to cancer cells and destroy them when activated by specific laser light. Brain tumor cells are killed wherever light penetrates.
Hemerion solutions are already clinically tested
Hemerion technology was first clinically evaluated in 2018 among 10 patients newly diagnosed with GBM and before any adjuvant treatment was delivered.
Complimentary clinical trials are still under way.
Solutions to tackle other types of cancers
Hemerion further develops its technology to tackle other types of cancers.
Demos and training
Hemerion team can demonstrate its technology on premises. Do not hesitate to contact us!
